Alicia Hong focuses her practice on China-related corporate transactions in the life sciences industry. She advises on cross-border mergers and acquisitions, licensing, co-development, strategic alliances, VC or PE investment and public listings, as well as joint venture, technology transfer and other collaboration projects.

Alicia has over 15 years of extensive experience in facilitating transactions between European, US and Asian companies, thanks to her knowledge of Chinese pharma and biotech industry landscape, the IP and regulatory development, as well as extended network of contacts in China including international pharma or biotech companies, PE and VC funds, state-owned enterprises and domestic private companies.

Prior to joining McDermott, Alicia has worked for other international law firms in both Shanghai and Frankfurt.

• Represented Vaximm AG in its outlicensing and investment agreement with a major Chinese pharmaceutical company
• Represented Mologen AG, a German public company in its licensing and co-development agreement with a well-known VC backed US-China biotech company for Mologen’s Phase III asset in the oncology space.
• Represented a Canada-based biotech company, Resverlogix, in a license and equity investment transaction with a Chinese publicly listed company Shenzhen Hepalink Pharmaceutical Co. for Resverlogix’s RVX-208 program*

Lire la suite

• Handelsblatt/Best Lawyers™ 2021 Germany: Leading Lawyer for Biotechnology Law and Life Sciences
• Leaders League’s 2019 guide, Innovation, Technology & Patents, “Excellent” in the Health, pharma & biotechnology category
• The Legal 500 EMEA 2019

Education
University of Warwick, LLM, 2002
East China University of Political Science and Law, LLB, 1998

Admissions
Germany

Lire la suite